Evidence map›Paper›PMID 25788958›Full record

ArticleHepatitis monthly2015

The effect of berberis vulgaris extract on transaminase activities in non-alcoholic Fatty liver disease.

Raziye Iloon Kashkooli, Seyed Saeed Najafi, Farkhondeh Sharif, Azadeh Hamedi, Mohammad Kazem Hoseini Asl, Majid Najafi Kalyani, Mehdi Birjandi

Open access · hybridAbstract read
In one paragraph

Article in Hepatitis monthly, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 4 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Review
  8. Evaluation of Cardiovascular Effects of the Hydroalcoholic Fruit Extract ofCardiovascular & hematological disorders drug targets · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Barberry in the treatment of obesity and metabolic syndrome: possible mechanisms of action.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018
    Review
  18. Review
  19. Iranian journal of basic medical sciences · 2017
    Article
  20. A review of the effects ofIranian journal of basic medical sciences · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Raziye Iloon KashkooliDepartment of Medical Surgical, School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Seyed Saeed NajafiDepartment of Medical Surgical, School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Farkhondeh SharifDepartment of Medical Surgical, School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Azadeh HamediDepartment of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Mohammad Kazem Hoseini AslGastroenterohepatology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, IR Iran.
Majid Najafi KalyaniDepartment of Medical Surgical, School of Nursing, Fasa University of Medical Sciences, Fasa, IR Iran.
Mehdi BirjandiDepartment of Biostatistics, School of Public Health, Lorestan University of Medical Sciences, Khoramabad, IR Iran.
Shiraz University of Medical Sciences · IRFasa University of Medical Sciences · IRLorestan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disorder in western countries and an important cause of liver cirrhosis, as well as liver failure. Up to now, 20‒40% of the individuals suffer from this disorder and its prevalence is estimated around 5‒30% in Asia. The NAFLD is one of the most prevalent causes for increases in liver enzymes and has a close relationship with obesity, dyslipidemia, hypertension, and type II diabetes. However, no definite treatment has been identified for it yet.

objectivesThe present study aimed to investigate the effect of berberis vulgaris extract in inducing changes in liver enzymes levels. PATIENTS AND

methodsThe present clinical trial was conducted on 80 patients, including 32 males (40%) and 48 females (60%), who were randomly assigned into two groups of case and control. All the patients had ultrasound evidence of lipid accumulation in the liver and increases in liver enzymes. The case group received two capsules (750 mg) containing berberis vulgaris extract every day for 3 months, while the control group was treated with placebo. The weight, liver transaminases levels and lipid profiles of the two groups were assessed before, during, and after the study.

resultsIn the case group, the mean serum levels of alanine transaminase (ALT) and aspartate transaminase (AST) decreased from 49 to 27.48 and 48.22 to 29.8 u/L, respectively, which was statistically significant compared to the control group (P < 0.001, P < 0.001). In the control group, the mean of ALT and AST decreased from 50.4 to 46.8 and 45.7 to 44.9 u/L, respectively. The difference was not statistically significant. In addition, a significant decrease was observed in weight, triglycerides, and cholesterol, while no significant change was found in fasting blood sugar, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL).

conclusionsConsidering the significant decrease in the liver enzymes, triglycerides and cholesterol after using berberis vulgaris extract, further studies with larger sample sizes will identify the accurate dose as well as duration of consumption for this extract, to recommend in the treatment of patients with NAFLD.

Indexed as

Alanine TransaminaseAspartate TransaminaseBerberisNon-Alcoholic Fatty Liver DiseaseTriglycerides

Identifiers

PMID25788958
PMCPMC4350248
OpenAlexW2120952434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.